These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34957716)

  • 1. [RASBURICASE TREATMENT FOR NEONATAL ACUTE KIDNEY INJURY - A CASE REPORT].
    Shasha-Lavsky H; Awadia P; Sheffer V; Weissman I
    Harefuah; 2021 Dec; 160(12):806-809. PubMed ID: 34957716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasburicase improves hyperuricemia in infants with acute kidney injury.
    Hobbs DJ; Steinke JM; Chung JY; Barletta GM; Bunchman TE
    Pediatr Nephrol; 2010 Feb; 25(2):305-9. PubMed ID: 19936796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury.
    Herrero-Goñi M; Zugazabeitia Irazábal A; Madariaga L; Chávarri Gil E; Gondra L; Aguirre Meñica M
    Clin Exp Nephrol; 2024 Jan; 28(1):13-22. PubMed ID: 37751013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
    Hooman N; Otukesh H
    Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
    Cho MH; Ahn YH; Lim SH; Kim JH; Ha IS; Cheong HI; Kang HG
    Pediatr Nephrol; 2020 Nov; 35(11):2183-2189. PubMed ID: 32561994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasburicase for acute kidney injury.
    Sinha R; Dugar P
    Indian Pediatr; 2013 Nov; 50(11):1051-2. PubMed ID: 24382901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasburicase for hyperuricemia in hemolytic uremic syndrome.
    Acosta AA; Hogg RJ
    Pediatr Nephrol; 2012 Feb; 27(2):325-9. PubMed ID: 22089328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
    Sestigiani E; Mandreoli M; Guardigli M; Roda A; Ramazzotti E; Boni P; Santoro A
    Nephron Clin Pract; 2008; 108(4):c265-71. PubMed ID: 18418005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
    Patel KS; Lau JE; Zembillas AS; Gallagher EM
    J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
    Lin PY; Lin CC; Liu HC; Lee MD; Lee HC; Ho CS; Chiu NC; Peng CC; Huang FY; Tsai JD
    Pediatr Crit Care Med; 2011 Nov; 12(6):e424-7. PubMed ID: 21572370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
    Moss JD; Wu M; Axelrod DM; Kwiatkowski DM
    Cardiol Young; 2019 Sep; 29(9):1160-1164. PubMed ID: 31451121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
    Malaguarnera M; Vacante M; Russo C; Dipasquale G; Gargante MP; Motta M
    Expert Opin Pharmacother; 2009 Apr; 10(5):737-42. PubMed ID: 19351224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasburicase therapy in acute hyperuricemia and renal dysfunction.
    Ronco C; Inguaggiato P; Bordoni V; De Cal M; Bonello M; Andrikos E; Assuman Y; Rattanarat R; Bellomo R
    Contrib Nephrol; 2005; 147():115-123. PubMed ID: 15604611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
    Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
    J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.